Our top pick for
Spero Therapeutics, Inc is a biotechnology business based in the US. Spero Therapeutics shares (SPRO) are listed on the NASDAQ and all prices are listed in US Dollars. Spero Therapeutics employs 57 staff and has a trailing 12-month revenue of around USD$11.1 million.
|52-week range||USD$5.25 - USD$15.49|
|50-day moving average||USD$13.7881|
|200-day moving average||USD$12.5443|
|Wall St. target price||USD$28.63|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.24|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$11.1 million|
|Gross profit TTM||USD$-47,628,000|
|Return on assets TTM||-39.97%|
|Return on equity TTM||-75%|
|Market capitalisation||USD$428.9 million|
TTM: trailing 12 months
There are currently 1.9 million Spero Therapeutics shares held short by investors – that's known as Spero Therapeutics's "short interest". This figure is 3.7% up from 1.8 million last month.
There are a few different ways that this level of interest in shorting Spero Therapeutics shares can be evaluated.
Spero Therapeutics's "short interest ratio" (SIR) is the quantity of Spero Therapeutics shares currently shorted divided by the average quantity of Spero Therapeutics shares traded daily (recently around 259380.60941828). Spero Therapeutics's SIR currently stands at 7.22. In other words for every 100,000 Spero Therapeutics shares traded daily on the market, roughly 7220 shares are currently held short.
However Spero Therapeutics's short interest can also be evaluated against the total number of Spero Therapeutics shares, or, against the total number of tradable Spero Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Spero Therapeutics's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Spero Therapeutics shares in existence, roughly 70 shares are currently held short) or 0.0761% of the tradable shares (for every 100,000 tradable Spero Therapeutics shares, roughly 76 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Spero Therapeutics.
Find out more about how you can short Spero Therapeutics stock.
We're not expecting Spero Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Spero Therapeutics's shares have ranged in value from as little as $5.25 up to $15.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Spero Therapeutics's is 1.56. This would suggest that Spero Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Its product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative infections in the hospital; and SPR720, an oral antibiotic for the treatment of pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics, Inc. has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; collaboration agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Qilian International Holding Group IPO, plus information on how to buy in.
Everything we know about the AbCellera Biologics IPO, plus information on how to buy in.
Steps to owning and managing CALM, with 24-hour and historical pricing before you buy.
Steps to owning and managing CRR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BG, with 24-hour and historical pricing before you buy.
Steps to owning and managing BCLI, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLBD, with 24-hour and historical pricing before you buy.
Steps to owning and managing BDTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing RILYO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASPN, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.